ClinicalTrials.gg

Program

Adalimumab

Also written as “adalimumab”, “MSB11022” and “M923”.

Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Crohn Disease · Colitis, Ulcerative · Hidradenitis Suppurativa, led by 17 companies.

Furthest: phase 4, since Sep 13, 2005149 company-led studies, 7 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbott620 open or runningphase 4since Sep 13, 2005Nov 1, 2002none ahead
AbbVie543 open or runningphase 4since May 25, 2010Sep 13, 2005Sep 2027phase 2 · NCT06257875
Alvotech Swiss60 open or runningphase 3since Feb 5, 2019Jun 8, 2018none ahead
Johnson & Johnson50 open or runningphase 3since Dec 18, 2013Dec 18, 2013none ahead
Fresenius Kabi40 open or runningphase 3since Jan 17, 2016Jan 17, 2016none ahead
Biocad30 open or runningphase 3since Mar 31, 2016Mar 16, 2015none ahead
Cinnagen20 open or runningphase 3since May 24, 2017May 24, 2017none ahead
Sino Biopharmaceutical22 open or runningphase 4since Apr 8, 2026Apr 8, 2026Apr 2028phase 4 · NCT07529925
Takeda20 open or runningphase 4since May 5, 2016Mar 15, 2015none ahead
Viatris20 open or runningphase 3since Nov 9, 2015Jun 3, 2015none ahead
care-arthritis-ltd10 open or runningphase 2since Feb 24, 2015Feb 24, 2015none ahead
Celltrion10 open or runningphase 3since Sep 18, 2019Sep 18, 2019none ahead
LG Chem10 open or runningphase 1since Jul 30, 2014Jul 30, 2014none ahead
mabscale-llc11 open or runningphase 3since Jul 5, 2023Jul 5, 2023none ahead
National Resilience10 open or runningphase 3since Jan 10, 2021Jan 10, 2021none ahead
prestige-biopharma-limited11 open or runningphase 1since Oct 1, 2021Oct 1, 2021Jun 2027phase 1 · NCT05108259
Samsung Bioepis10 open or runningphase 1since Aug 13, 2020Aug 13, 2020none ahead

Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany, mylan-gmbh, pharm-olam-llc, ppd-development-lp, pra-health-sciences, ist-gmbh-germany, parexel, pivotal-s-l, GlaxoSmithKline, Regeneron Pharmaceuticals, Eisai and abbott-japan-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 45 studies since Jun 14, 2012.

  1. Sep 18, 2019Celltrion's first study: phase 3 study in Arthritis, RheumatoidNew to CelltrionCelltrion · NCT04171414 · 62 enrolled · Poland
  2. Dec 10, 2019Phase 3 study in RAAlvotech Swiss · NCT04224194 · 107 enrolled · Georgia, Ukraine
  3. May 15, 2020Phase 3 study in Plaque PsoriasisAlvotech Swiss · NCT04453137 · 567 enrolled · Georgia, Iceland, Poland and more
  4. Aug 13, 2020Samsung Bioepis's first study: phase 1 study in HealthyNew to Samsung BioepisSamsung Bioepis · NCT04514796 · 188 enrolled · Germany
  5. Jan 10, 2021National Resilience's first study: phase 3 study in Mild to Moderate COVID-19New to National ResilienceNational Resilience · NCT04705844
  6. Oct 1, 2021prestige-biopharma-limited's first study: phase 1 study in Healthy VolunteersNew to prestige-biopharma-limitedprestige-biopharma-limited · NCT05108259 · 160 enrolled · Spain
  7. Jun 8, 2022Phase 4 study in Non-infectious Intermediate Posterior- or Pan-uveitisAbbVie · NCT05414201 · 87 enrolled · China
  8. Apr 4, 2023Phase 3 study in Arthritis, RheumatoidAbbVie · NCT05814627 · 487 enrolled · United States, Argentina, Belgium and more
  9. May 22, 2023Phase 1 study in HealthyJohnson & Johnson · NCT05884242 · 20 enrolled · Belgium
  10. Jul 5, 2023mabscale-llc's first study: phase 3 study in Plaque PsoriasisNew to mabscale-llcmabscale-llc · NCT06005532 · 494 planned · Russian Federation
  11. Oct 2, 2023Phase 2 study in Colitis, UlcerativeAbbVie · NCT06257875 · 156 enrolled · United States, Australia, Austria and more
  12. Oct 20, 2023Phase 3 study in Arthritis, JuvenileAbbVie · NCT06100744 · 40 planned · United States, Australia, Canada and more
  13. Sep 12, 2025Phase 1 study in Healthy Adult MaleBiocad · NCT07181694 · 444 enrolled · Russia
  14. Apr 8, 2026Sino Biopharmaceutical's first studies: 2 phase 4 studiesNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT07529925, NCT07564505

Ahead

  1. Jun 2027Primary completion: phase 1 study in Healthy Volunteersprestige-biopharma-limited · NCT05108259
  2. Sep 2027Primary completion: phase 2 study in Colitis, UlcerativeAbbVie · NCT06257875
  3. Apr 2028Primary completion: phase 4 study in Severe Plaque Psoriasis in Chinese ChildrenSino Biopharmaceutical · NCT07529925
  4. Mar 2029Primary completion: phase 4 study in Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's DiseaseSino Biopharmaceutical · NCT07564505

TargetBeta

TNF →read by rule
“TNF-alpha inhibitor”ChEMBL 37, by rule

Other programs on TNF

ProgramCompanyFurthest phaseStudies
Brentuximab VedotinrulePfizerphase 437
CHS-1420rulenanjing-king-friend-biochemical-pharmaceutical-co-ltdphase 32
brivekimigSanofiphase 26
Hadlimarulebiora-therapeutics-incphase 11

Studies

The newest 60 of 149 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07564505Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease · China4RecruitingSino BiopharmaceuticalMar 202930
NCT07529925Severe Plaque Psoriasis in Chinese Children4Not yet recruitingSino BiopharmaceuticalApr 202830
NCT07181694Healthy Adult Male · Russia1CompletedBiocadFeb 12, 2026444
NCT06100744Arthritis, Juvenile · United States, Australia, Canada and more3RecruitingAbbVieSep 202640
NCT06257875Colitis, Ulcerative · United States, Australia, Austria and more2Active, not recruitingAbbVieSep 2027156
NCT06005532Plaque Psoriasis · Russian Federation3Recruitingmabscale-llcMar 2025494
NCT05884242Healthy · Belgium1CompletedJohnson & JohnsonAug 1, 202320
NCT05814627Arthritis, Rheumatoid · United States, Argentina, Belgium and more3CompletedAbbVieJul 15, 2026487
NCT05414201Non-infectious Intermediate Posterior- or Pan-uveitis · China4CompletedAbbVieJun 10, 202487
NCT05108259Healthy Volunteers · Spain1Active, not recruitingprestige-biopharma-limitedJun 2027160
NCT04705844Mild to Moderate COVID-193WithdrawnNational ResilienceSep 20220
NCT04514796Healthy · Germany1CompletedSamsung BioepisMay 15, 2021188
NCT04453137Plaque Psoriasis · Georgia, Iceland, Poland and more3CompletedAlvotech SwissMay 31, 2021567
NCT04224194RA · Georgia, Ukraine3CompletedAlvotech SwissJul 8, 2020107
NCT04171414Arthritis, Rheumatoid · Poland3CompletedCelltrionNov 4, 201962
NCT04018599Arthritis, Rheumatoid · United States1CompletedFresenius KabiMar 17, 2020216
NCT03983876Phase 1 · New Zealand1CompletedAlvotech SwissDec 3, 2019207
NCT03849404Plaque Psoriasis · Estonia, Georgia, Poland and more3CompletedAlvotech SwissDec 23, 2019413
NCT03849313Healthy Volunteers · Australia, New Zealand1CompletedAlvotech SwissFeb 17, 2020390
NCT03823391Arthritis, Rheumatoid · United States, Germany, Hungary and more2CompletedAbbVieApr 8, 202048
NCT03579823Healthy Volunteers · Australia1CompletedAlvotech SwissAug 24, 201824
NCT03311464Pyoderma Gangrenosum · Japan3CompletedAbbVieAug 20, 201922
NCT03273192Bioequivalence · Iran, Islamic Republic of1CompletedCinnagenAug 6, 201774
NCT03172325Active Rheumatoid Arthritis · Iran, Islamic Republic of3CompletedCinnagenAug 17, 2016136
NCT03052322Moderate to Severe Rheumatoid Arthritis · Bulgaria, Czechia, Germany and more3CompletedFresenius KabiMay 28, 2018288
NCT03014947Healthy Subjects1CompletedFresenius KabiDec 2014237
NCT02904902Hidradenitis Suppurativa · Japan3CompletedAbbVieSep 1, 201715
NCT02897115Axial Spondyloarthritis4TerminatedAbbVieDec 21, 201722
NCT02814175Arthritis, Psoriatic · United States, Australia, Brazil and more4CompletedAbbVieSep 23, 2019246
NCT02808975Hidradenitis Suppurativa · United States, Belgium, Canada and more4CompletedAbbVieMay 16, 2019206
NCT02764762Crohn Disease · United States, Canada4CompletedTakedaSep 22, 202055
NCT02762955Psoriasis · Russian Federation3CompletedBiocadDec 2017344
NCT02722044Arthritis, Rheumatoid · United States3CompletedJohnson & JohnsonFeb 21, 201733
NCT02675023Healthy · United States, United Kingdom1CompletedJohnson & JohnsonJul 2016603
NCT02660580Psoriasis · United States, Bulgaria, Canada and more3CompletedFresenius KabiDec 31, 2016443
NCT02632175Colitis, Ulcerative · United States, Japan, Poland and more3CompletedAbbVieApr 8, 202559
NCT02629159Arthritis, Rheumatoid · United States, Argentina, Australia and more3Active, not recruitingAbbVieOct 27, 20171,629
NCT02714322Psoriasis · Bulgaria, Estonia, Hungary and more3CompletedViatrisMay 2016294
NCT02581345Psoriasis · United States, Bulgaria, Canada and more3CompletedJohnson & JohnsonApr 4, 2017572
NCT02533375Psoriasis3CompletedAbbVieSep 15, 201610
NCT02499783Crohn Disease3CompletedAbbVieMay 19, 2017205
NCT02472912Healthy Volunteers · Belgium1CompletedViatrisMay 2015270
NCT02395055Healthy · Russian Federation1CompletedBiocadOct 201594
NCT02393378Arthritis, Rheumatoid · Czechia, Estonia, Russian Federation and more2TerminatedTakedaJun 27, 20167
NCT02471118Osteoarthritis, Knee · Canada2Completedcare-arthritis-ltdMar 202162
NCT02206867Healthy Subjects1CompletedLG ChemFeb 2015116
NCT02198651Arthritis, Rheumatoid · United States, Australia, Austria and more4CompletedAbbVieMay 3, 2018149
NCT02196701Psoriasis3CompletedAbbVieMar 17, 201746
NCT02185014Crohn Disease3CompletedAbbVieNov 3, 2017252
NCT02148718Crohn Disease4CompletedAbbVieAug 2016100
NCT02065622Colitis, Ulcerative · United States, Austria, Belgium and more3CompletedAbbVieSep 5, 2019952
NCT02065570Crohn Disease · United States, Austria, Belgium and more3CompletedAbbVieJan 30, 2020514
NCT02065557Colitis, Ulcerative · United States, Australia, Austria and more3CompletedAbbVieFeb 7, 2020101
NCT02019472Arthritis, Rheumatoid · United States, Bulgaria, Chile and more3CompletedJohnson & JohnsonAug 17, 2016559
NCT02016482Nail Psoriasis3CompletedAbbVieOct 2015217
NCT02015793Crohn Disease2CompletedAbbVieFeb 201530
NCT01958827Crohn Disease3CompletedAbbVieMar 201528
NCT01808118Axial Spondyloarthritis3CompletedAbbVieFeb 21, 2017673
NCT01752855Arthritis, Rheumatoid · United States, Belgium, Czech Republic and more2CompletedAbbVieOct 201388
NCT01712178Arthritis, Rheumatoid · United States, Belgium, Czech Republic and more2CompletedAbbVieMay 2013100

How it is read

Names in the registry

  • “Adalimumab”, 69 entries
  • “adalimumab”, 63 entries
  • “MSB11022”, 3 entries
  • “M923”, 3 entries
  • “Humira (adalimumab)”, 3 entries

Codes read as this program: AVT02.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.